Oncologist with an interest in Health Services Research and GU Oncology
Stanford, CA
Joined July 2018
- Tweets19
- Following139
- Followers137
- Likes140
Divya A Parikh retweeted
If you have ever been diagnosed with stage 0-3 breast cancer, please consider helping Stanford breast cancer researchers understand your perspectives on a new kind of clinical trial by filling out this short survey: bit.ly/3VXEQ6q #bcsm (retweets appreciated!)
Divya A Parikh retweeted
How do we overcome multi-factorial barriers to receipt of high quality cancer treatments? Dr @meera_ragavan at @ASCO #ASCOQLTY22 #PharmacoEquity
Proud of Dr @meera_ragavan @CostsofCare Fellow speaking on #pharmacoEquity @ASCO #ASCOQLTY22 🙌
Pembrolizumab for non-muscle-invasive bladder cancer – is it worth the cost? @arkhaki @SWilliams_MD
authors.elsevier.com/c/1eXVp…
Divya A Parikh retweeted
“A seemingly harmless Rx can actually cause great economic burden to pts.” – @guptaarjun90 on new @ASCO_pubs #JCOOP article & #ASCOQLTY21 abstract covering 💲 burden of Rx for cancer-related symptoms fal.cn/3iCKY #financialtoxicity #ASCODailyNews @OncoAlert @UMNews
Such an honor to present at #ASCO quality alongside my brilliant mentor @manalipatelmd! So grateful for opportunity to present our work and the thoughtful discussion by @MBakitas.
This Post is from an account that no longer exists. Learn more
Divya A Parikh retweeted
@sandysrimd of @StanfordCancer discusses advances in the management of metastatic castration-resistant #ProstateCancer at the #NCCN21 Virtual Annual Conference: buff.ly/3qzcCA8 #CRPC #PCSM
Our study of #financialtoxicity in disparate #cancercare systems was published in @ASCO_pubs #JCOOP! Thanks to the collaborative team @VAPaloAlto @StanfordCancer and SCVMC @meera_ragavan @ritikulocyte @manalipatelmd
ascopubs.org/doi/10.1200/OP.…
Divya A Parikh retweeted
So tragic that in the wealthiest country in the world the main driving forces behind treatment preferences in #breastcancer are cost and ability to get back to work ASAP #ASCOQLTY20 @asco #healthequity – at Tlalpan, Distrito Federal
Divya A Parikh retweeted
As #ASCO20 wraps, the US remains in turmoil. For those unable to see the inequities at the root of this strife, I will highlight 1 graph from our study. Even as we make progress over time, FAR MORE black patients die from #cancer than white patients.
This is not a just society.
We are conducting a study on the impact of #COVID19 on cancer #providers and their practice. Help us inform ways to improve #cancercare and change policy by taking our provider survey: redcap.stanford.edu/surveys/…
Divya A Parikh retweeted
Great guide for #GUcancers in uncharted times. We should consider when discussing our own practices tomorrow @Daniel_J_George @DukeGUCancer
Rethinking treatment for urology cancer. Silke Gillessen and myself giving some practical considerations #COVID19 Coming shortly in @EUplatinum
Divya A Parikh retweeted
Congratulations to the authors on publication of this patient-inclusive registry data for ROS1+ cancers. Characteristics of Patients With ROS1+ Cancers: Results From First Patient-Designed, Global, Pan-Cancer ROS1 Data Repository | JCO Oncology Practice ascopubs.org/doi/abs/10.1200…
A Call to Action Toward Patient Centricity: GU Cancers Symposium to Feature More Financial and Quality-of-Life Research dailynews.ascopubs.org/do/10…
Divya A Parikh retweeted
Huge cost savings with docetaxel vs abiraterone in HSPC. bit.ly/2lT6UMg
Divya A Parikh retweeted
Too often people are #underinsured and financially burdened by the cost of #cancer care. Faced with a choice between their money and their lives, some patients lose both.
Proud of our #graphicmedicine OP-ED in @latimes @NathanAGray #financialtoxicity
latimes.com/opinion/story/20…
Divya A Parikh retweeted
Patient-reported outcomes are widely collected in routine care through Epic at @UofR, by >240k patients with >98% compliance - but clinicians only use the #PRO data 40% of the time - showing need to engage clinicians @clevinger_kc @FDAOncology @ASCO @pkluetz – at White Oak, MD
Divya A Parikh retweeted
I'm honored to discuss plenary LBA1, a study on healthcare access, equity, & real-world data--topics of global relevance
A non-traditional @ASCO plenary deserves a non-traditional approach so I'm live tweeting my talk thanks to @DukeGUCancer! #ASCO19 #ASCOhealthequity Pls share!
